<DOC>
	<DOCNO>NCT01179347</DOCNO>
	<brief_summary>To date , formal clinical study complete use tiotropium CF patient . While large body evidence demonstrate efficacy safety tiotropium patient Chronic Obstructive Pulmonary Disease ( COPD ) , relatively little known efficacy safety patient diagnosis cystic fibrosis . Therefore , Boehringer Ingelheim propose profile long act anticholinergic tiotropium generate adequate clinical data use bronchodilator paediatric adult CF . The phase III trial ( 205.438 ) part approve Paediatric Investigation Plan ( PIP ) agree Spiriva速 Respimat速 Cystic Fibrosis .</brief_summary>
	<brief_title>Tiotropium Bromide Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients document diagnosis Cystic Fibrosis ( CF ) ( positive sweat chloride &gt; =60 mEq/liter , pilocarpine iontophoresis ) and/or genotype two identifiable mutation . 2 . Male female patient ( child less 12 year adolescent &gt; 12 year ) . 3 . Patients &gt; =5 year age must able perform acceptable spirometric maneuver , accord American Thoracic Society ( ATS ) standard . 4 . Prebronchodilator Forced Expiratory Volume One Second ( FEV1 ) &gt; 25 % predicted value . 5 . Prebronchodilator FEV1 Visit 2 must within 15 % FEV1 Visit 1 . 6 . No evidence respiratory tract infection pulmonary exacerbation require use intravenous/oral/inhaled antibiotic , oral corticosteroid within 2 week screen . 7 . The patient patient 's legally acceptable representative must able give informed consent . 8 . Patients cycle TOBI速 regimen must complete least 2 cycle every month TOBI速 administration prior screen visit . 9 . Patients daily inhale antibiotic use must stabilize least 6 week prior Visit 1 ( screen ) . 10 . Patients previously participate study 205.339 also select . Exclusion criterion : 1 . Patients know hypersensitivity study drug 2 . Patients participate another study Investigational drug within one month precede screen visit . 3 . Patients currently participate another trial . Observational study allow . Permission obtain sponsor study . 4 . Patients know relevant substance abuse , include alcohol drug abuse . 5 . Adolescent adult female patient pregnant lactating , include female positive serum pregnancy test screening . 6 . Female patient child bear potential use medically approve form contraception . 7 . Clinically significant disease medical condition CF CFrelated condition , opinion Investigator , would compromise safety patient quality data . Patients diabetes may participate disease good control prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>